WAVE LIFE SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.66 USD | -1.69% |
|
-4.31% | -7.72% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 274.8 | 383.9 | 184.7 | 608.4 | 601.6 | 569.8 | - | - |
| Enterprise Value (EV) 1 | 127.7 | 199.4 | 34.17 | 519.9 | 401.3 | 408.6 | 502 | 569.8 |
| P/E ratio | -1.4 x | -2.06 x | -1.33 x | -3.41 x | -9.35 x | -4.61 x | -4.36 x | -5.53 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.2 x | 19.1 x | 4.51 x | 167 x | 5.31 x | 7.46 x | 10.8 x | 6.52 x |
| EV / Revenue | 7.99 x | 9.93 x | 0.83 x | 142 x | 3.54 x | 5.35 x | 9.5 x | 6.52 x |
| EV / EBITDA | -641,191 x | - | - | - | - | - | - | - |
| EV / FCF | -0.66 x | -1.7 x | -0.38 x | -4.03 x | -19.5 x | -3.22 x | -2.94 x | -3.01 x |
| FCF Yield | -151% | -58.9% | -262% | -24.8% | -5.12% | -31.1% | -34.1% | -33.3% |
| Price to Book | 3.79 x | 4.64 x | 4.65 x | -13.5 x | 15.2 x | 7.9 x | -25.9 x | - |
| Nbr of stocks (in thousands) | 34,290 | 48,778 | 58,833 | 86,910 | 119,138 | 122,284 | - | - |
| Reference price 2 | 8.015 | 7.870 | 3.140 | 7.000 | 5.050 | 4.660 | 4.660 | 4.660 |
| Announcement Date | 3/2/20 | 3/4/21 | 3/3/22 | 3/22/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15.98 | 20.08 | 40.96 | 3.649 | 113.3 | 76.38 | 52.83 | 87.41 |
| EBITDA | -199.1 | - | - | - | - | - | - | - |
| EBIT 1 | -208.3 | -153.4 | -127 | -162.7 | -68 | -130.3 | -135.1 | -133.1 |
| Operating Margin | -1,303.37% | -763.94% | -310.07% | -4,459.3% | -60.01% | -170.58% | -255.77% | -152.29% |
| Earnings before Tax (EBT) 1 | -193.6 | -150.8 | -122.4 | -161.1 | -58.19 | -122.3 | -128.6 | -126.7 |
| Net income 1 | -193.6 | -149.9 | -122.2 | -161.8 | -57.51 | -119 | -141.1 | -126.7 |
| Net margin | -1,211.52% | -746.68% | -298.42% | -4,434.72% | -50.76% | -155.84% | -267.12% | -145.01% |
| EPS 2 | -5.720 | -3.820 | -2.360 | -2.050 | -0.5400 | -1.010 | -1.068 | -0.8433 |
| Free Cash Flow 1 | -192.1 | -117.4 | -89.55 | -129.1 | -20.55 | -127 | -171 | -189.6 |
| FCF margin | -1,202.21% | -584.6% | -218.61% | -3,539.11% | -18.13% | -166.33% | -323.73% | -216.92% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/4/21 | 3/3/22 | 3/22/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 36.42 | 1.765 | 1.75 | 0.375 | 0.285 | 1.239 | 12.93 | 22.11 | 49.21 | 29.06 | 22.95 | 19.61 | 16.91 | 16.91 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.607 | -36.11 | -38.09 | -42.16 | -38.9 | -43.56 | -30.28 | -23.47 | 4.444 | -18.68 | -25.08 | -31.83 | -36.56 | -37.32 | -37.25 |
| Operating Margin | -20.89% | -2,045.89% | -2,176.8% | -11,243.73% | -13,648.77% | -3,515.98% | -234.24% | -106.18% | 9.03% | -64.3% | -109.28% | -162.31% | -216.16% | -220.75% | -248.33% |
| Earnings before Tax (EBT) 1 | -6.23 | -34.99 | -37.81 | -41.3 | -39 | -43.03 | -27.4 | -21.1 | 6.575 | -16.26 | -23.08 | -29.84 | -34.56 | -35.33 | -35.9 |
| Net income 1 | -6.23 | -34.78 | -37.81 | -41.3 | -39 | -43.71 | -27.4 | -21.1 | 6.995 | -16.26 | -23.96 | -28.73 | -32.85 | -33.86 | -35.9 |
| Net margin | -17.1% | -1,970.82% | -2,160.8% | -11,012.27% | -13,685.61% | -3,527.76% | -211.97% | -95.47% | 14.21% | -55.95% | -104.44% | -146.49% | -194.25% | -200.29% | -239.33% |
| EPS 2 | -0.1200 | -0.6100 | -0.6200 | -0.6200 | -0.4200 | -0.4500 | -0.2700 | -0.2000 | 0.0700 | -0.1500 | -0.2140 | -0.2400 | -0.2740 | -0.2820 | -0.2750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/3/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/22/23 | 5/3/23 | 8/3/23 | 11/9/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 147 | 184 | 151 | 88.5 | 200 | 161 | 67.9 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -192 | -117 | -89.6 | -129 | -20.5 | -127 | -171 | -190 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.110 | 1.700 | 0.6700 | -0.5200 | 0.3300 | 0.5900 | -0.1800 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 3.92 | 1.39 | 0.56 | 1.36 | 1.12 | 1.03 | 1.05 | 1.12 |
| Capex / Sales | 24.51% | 6.91% | 1.37% | 37.3% | 0.98% | 1.34% | 1.99% | 1.28% |
| Announcement Date | 3/2/20 | 3/4/21 | 3/3/22 | 3/22/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.66
USD
Average target price
13
USD
Spread / Average Target
+178.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.72% | 570M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- WVE Stock
- Financials Wave Life Sciences Ltd.
